The New York Times and ProPublica have teamed up to investigate who is to blame for skyrocketing drug prices — and have turned up some surprising answers.
Outcry has been building over the rising cost of brand-name medications, but the price of generic drugs has been moving in the opposite direction. The stock prices of generic manufacturers have tumbled, but many consumers aren’t paying less at the pharmacy counter.
Faced with competition, some pharmaceutical companies are cutting deals with insurance companies to favor their brand-name products over cheaper generics. Insurers pay less, but sometimes consumers pay more.
Pharmaceutical companies are increasingly agreeing to refund money if patients don't respond to medications as expected. The Trump administration is intrigued, but critics say the deals are unlikely to reduce consumers’ bills.
Amid public concern over spiking drug prices, a powerful middleman is suing a tiny drugmaker over unpaid rebates and fees. The maker calls the suit baseless; analysts say the suit offers a window into an opaque world.
- How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits
- How Columbia Ignored Women, Undermined Prosecutors and Protected a Predator For More Than 20 Years
- Idaho Banned Abortion. Then It Turned Down Supports for Pregnancies and Births.
- Louisiana Supreme Court Ruling Overturns Reform Law Intended to Fix “Three-Strikes” Sentences
- Philips Kept Complaints About Dangerous Breathing Machines Secret While Company Profits Soared